2024-10-13 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) over the analyzed period. Its cumulative return of 899.89 is significantly higher than VOO's return of 135.82. This difference translates to a relative divergence of 94.74%, indicating that LLY's performance is currently at the 94.74th percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

LLY's current closing price is $932.06.  It has seen a positive trend in recent weeks, with the 5-day moving average at $914.5, the 20-day moving average at $906.22, and the 60-day moving average at $894.98. This suggests an upward momentum in the short to medium term. 

**3. Technical Indicators:**

* **RSI:** The RSI value of 54.89 suggests that LLY is currently in a neutral territory, neither overbought nor oversold. 
* **PPO:** The PPO value of 0.31 indicates a bullish signal, suggesting potential momentum in the stock's price.
* **Delta_Previous_Relative_Divergence:** The negative value of -0.2 suggests a slight short-term downward trend in the relative divergence. However, this needs to be further investigated in conjunction with other indicators.
* **Expected Return:** The expected return of 24.91% represents the potential 5-year return relative to the S&P 500, assuming current trends persist. This is a significant potential gain, but remember, future performance is not guaranteed.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

LLY has consistently surpassed revenue estimates in recent quarters. The most recent earnings report for Q2 2024, released on 08/08/2024, showed EPS of $3.29, beating estimates by $0.44. The revenue for the quarter reached $11.30 billion, exceeding expectations by $1.38 billion. This strong performance reflects the company's robust growth and market share expansion.  Analyst expectations for future quarters are currently positive, with analysts citing strong demand for LLY's key products, particularly in the diabetes and oncology segments.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Recent market sentiment towards LLY is positive, driven by consistent earnings beats and strong growth in key therapeutic areas. The company's strong market position, innovative pipeline, and recent acquisition of a significant portion of Boehringer Ingelheim's diabetes portfolio have all contributed to a favorable outlook.
* **Analyst Opinions:**  Most analysts have a "buy" or "strong buy" rating on LLY. The consensus target price indicates an upside potential of around 15% from current levels.
* **Performance Highlights:** LLY has delivered impressive growth in its diabetes and oncology segments, driven by the success of its key products like Trulicity and Verzenio. The company's recent acquisitions and investments in R&D are also contributing to its strong performance.

**6. Overall Analysis:**

LLY's strong performance, positive technical indicators, and positive earnings outlook suggest a strong potential for continued growth. The company's leadership position in key therapeutic areas, commitment to innovation, and robust pipeline make it a compelling investment. While some short-term volatility may occur, LLY's long-term prospects appear favorable. 

**7. Recommendation:**

Based on the analysis, LLY appears to be a strong investment candidate. The combination of strong financials, positive analyst sentiment, and a favorable market outlook indicates a high potential for future growth. Investors seeking exposure to the healthcare sector, particularly in the diabetes and oncology segments, could consider adding LLY to their portfolios. However, it is crucial to consult with a financial advisor before making any investment decisions. 
